Track TC BioPharm (Holdings) plc American Depositary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

TC BioPharm (Holdings) plc American Depositary Shares TCBP Open TC BioPharm (Holdings) plc American Depositary Shares in new tab

0.5000 USD
EPS
-290.42
P/B
0.02
ROE
-577.04
Beta
0.01
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-290.42
Book Value26.11
Price to Book0.02
Debt/Equity82.50
% Insiders0.006%
Estimates
Forward P/E-0.11
Forward EPS-4.60

DCF Valuation

Tweak assumptions to recompute fair value for TC BioPharm (Holdings) plc American Depositary Shares (TCBP)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

TC BioPharm (Holdings) plc American Depositary Shares Logo TC BioPharm (Holdings) plc American Depositary Shares Analysis (TCBP)

United Kingdom Health Care Official Website Stock

Is TC BioPharm (Holdings) plc American Depositary Shares a good investment? TC BioPharm (Holdings) plc American Depositary Shares (TCBP) is currently trading at 0.5000 USD.

Investor FAQ

Does TC BioPharm (Holdings) plc American Depositary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is TC BioPharm (Holdings) plc American Depositary Shares?

TC BioPharm (Holdings) plc American Depositary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Exchange Ticker
NMS (United States) TCBP

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Jan. 16, 2025 1.250000
Nov. 21, 2022 0.020000
Dec. 15, 2023 0.050000
Aug. 5, 2024 0.100000
Jan. 7, 2025 1.250000
Feb. 10, 2025 0.050000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion